NexGenix Pharmaceuticals Holdings Inc

NexGenix Pharmaceuticals Holdings Inc. is a privately held company based in New York, New York. The company employs three people and reported $2.5 million in revenue. NexGenix specializes in the discovery and development of targeted therapies. NexGenix focuses on developing the "next generation" of treatments for various diseases, including cancer and neurological disorders like glioblastoma, neurodegenerative diseases, neurofibromatosis, and autism-spectrum disorders. Their core technology centers around resorcylic macrolides, potent inhibitors of the chaperone heat shock protein 90 (Hsp90). This approach targets the misregulation of protein homeostasis, a common factor in many diseases. The company's Hsp90 inhibitors, derived from the potent compound radicicol, hold the potential to become leading drugs in their class. NexGenix has assembled a team of world-renowned scientific advisors and collaborators with expertise in protein folding, kinase signaling, oncogenesis, and neurodegenerative diseases. Their intellectual property portfolio encompasses their key research areas. For more information, visit NexGenix Pharmaceuticals Holdings Inc. at nexgenixpharm.com.